Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. ExpreS2ion Biotech Holding AB (publ)
  6. Summary
    EXPRS2   SE0008348262

EXPRES2ION BIOTECH HOLDING AB (PUBL)

(EXPRS2)
  Report
Delayed Nasdaq Stockholm  -  05/20 11:29:38 am EDT
15.10 SEK   -1.76%
05/09Scientific article about the advantageous S2-based protein secretion system ExpreS2 and a moderate-throughput research variant called FAS2FURIOUS
AQ
05/05ExpreS2ion announces final outcome of fully guaranteed rights issue of approximately SEK 73 million
AQ
05/05ExpreS2ion Up 34% After Releasing Further Data From Booster Vaccine Clinical Trial
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
13.86(c) 14(c) 14.23(c) 15.37(c) 15.1(c) Last
54 276 73 356 188 381 312 956 192 212 Volume
+4.76% +1.01% +1.64% +8.01% -1.76% Change
More quotes
Estimated financial data (e)
Sales 2022 12,0 M 1,21 M 1,21 M
Net income 2022 -80,0 M -8,07 M -8,07 M
Net Debt 2022 42,0 M 4,24 M 4,24 M
P/E ratio 2022 -4,11x
Yield 2022 -
Sales 2023 286 M 28,8 M 28,8 M
Net income 2023 142 M 14,3 M 14,3 M
Net cash position 2023 103 M 10,4 M 10,4 M
P/E ratio 2023 2,31x
Yield 2023 -
Capitalization 724 M 73,0 M 73,0 M
EV / Sales 2022 63,8x
EV / Sales 2023 2,17x
Nbr of Employees 26
Free-Float 87,1%
More Financials
Company
ExpreS2ion Biotech Holding AB is a Sweden-based biopharmaceutical company. The Company specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The Company's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable... 
Read more
Sector
Pharmaceuticals
Calendar
05/19Earnings Release
More about the company
Ratings of ExpreS2ion Biotech Holding AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about EXPRES2ION BIOTECH HOLDING AB (PUBL)
05/09Scientific article about the advantageous S2-based protein secretion system ExpreS2 and..
AQ
05/05ExpreS2ion announces final outcome of fully guaranteed rights issue of approximately SE..
AQ
05/05ExpreS2ion Up 34% After Releasing Further Data From Booster Vaccine Clinical Trial
MT
05/05Positive Omicron data from the COVID-19 Phase II trial reported for the ABNCoV2 vaccine
AQ
05/05Expres2ion Biotech Holding AB Announces Positive Omicron Data from the Covid-19 Phase I..
CI
05/04ExpreS2ion - Annual report for 2021 published
AQ
04/25EXPRES2ION BIOTECH : Proxy Form
PU
04/25EXPRES2ION BIOTECH : Notification and form for advance voting
PU
04/25EXPRES2ION BIOTECH : Bilingual version where the Swedish text prevails
PU
04/25Notice of Annual General Meeting in ExpreS2ion Biotech Holding AB
AQ
04/21BIOSTOCK STUDIO : Expres2ion's CEO gives status update
AQ
04/20ExpreS2ion publishes video presentation
AQ
04/19Frontiers in Immunology publishes article about ABNCoV2
AQ
04/19BIOSTOCK INVESTOR PITCH : ExpreS2ion Biotechnologies
AQ
04/13ExpreS2ion publishes prospectus in connection with fully guaranteed rights issue of app..
AQ
More news
News in other languages on EXPRES2ION BIOTECH HOLDING AB (PUBL)
05/05Expres2ion Biotech Holding AB (Publ) annonce des données omicroniques positives issues ..
02/28Expres2ion Biotech Holding AB (Publ) fournit des résultats positifs supplémentaires de ..
02/24ExpreS2ion Biotech Holding AB (publ) annonce ses résultats pour le quatrième trimestre ..
02/24ExpreS2ion Biotech Holding AB (publ) annonce ses résultats pour l'exercice clos le 31 d..
2021ExpreS2ion Biotech Holding AB nomme Mattis F. Ranthe au poste de médecin en chef, à com..
More news
Chart EXPRES2ION BIOTECH HOLDING AB (PUBL)
Duration : Period :
ExpreS2ion Biotech Holding AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXPRES2ION BIOTECH HOLDING AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 15,37 SEK
Average target price 86,00 SEK
Spread / Average Target 460%
EPS Revisions
Managers and Directors
Bent U. Frandsen Chief Executive Officer
Keith Alexander Chief Financial Officer
Martin Roland Jensen Chairman
Max M. Søgaard Vice President-Technology, Research & Development
Mette Thorn Vice President-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
EXPRES2ION BIOTECH HOLDING AB (PUBL)-57.12%73
CSL LIMITED-5.75%93 171
SAMSUNG BIOLOGICS CO.,LTD.-11.85%44 721
BIOGEN INC.-19.52%28 278
WUXI BIOLOGICS (CAYMAN) INC.-43.60%28 063
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-26.31%21 889